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Background: Cistanche tubulosa (Schenk) R. Wight (CT) is commonly used to treat forgetfulness by traditional
Chinese physicians. This study presents the ameliorating effects of CT extract which was quantified with three
phenylpropanoid glycosides in Alzheimer’s disease (AD)-like rat model.
Methods: Amyloid β peptide 1-42 (Aβ 1-42) intracisternally infused to rats by osmotic pump (Alzet 2002) was used
as an AD-like rat model. The major pathological makers were measured including Aβ 1-42 immunohistochemical
stain, behavioral tests (inhibitory avoidance task and Morris water maze) and central neurotransmitter functions.
Results: Aβ 1-42 caused the cognitive deficits, the increase in the amyloid deposition and acetylcholinesterase
activities, and the decrease in the levels of brain’s acetylcholine and dopamine. Daily administration of CT extract
throughout Aβ 1-42 infusion periods ameliorated the cognitive deficits, decreased amyloid deposition and reversed
cholinergic and hippocampal dopaminergic dysfunction caused by Aβ 1-42. Donepezil also ameliorated the
cognitive dysfunction, but only blocked the amyloid deposition and cholinergic dysfunction caused by Aβ 1-42.
Conclusions: We suggest that CT extract, containing enough echinacoside and acteoside, ameliorated the
cognitive dysfunction caused by Aβ 1-42 via blocking amyloid deposition, reversing cholinergic and hippocampal
dopaminergic neuronal function.
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Alzheimer’s disease (AD), a progressive neurodegenerative
disorder, is characterized by cognitive deficits and three
neuropathological hallmarks: neuronal loss, senile plaques
and neurofibrillary tangles [1]. The major pathogenesis of
AD includes the cholinergic hypothesis and the amyloid
cascade hypothesis [2]. The core feature of amyloid cas-
cade hypothesis is the formation of the byproduct amyloid
β peptide (Aβ) from amyloid precursor protein via amyloi-
dogenic pathway [1,2]. When Aβ is deposited in the brain,
it is associated with cerebral neuronal loss, particularly the* Correspondence: crw@mail.cmu.edu.tw
†Equal contributors
1Department of Chinese Pharmaceutical Sciences and Chinese Medicine
Resources, College of Pharmacy, China Medical University, No. 91, Hsieh Shih
Road, Taichung 40402, Taiwan
Full list of author information is available at the end of the article
© 2014 Wu et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.degeneration of cholinergic neuronal circuits in the basal
forebrain (the cholinergic hypothesis) [2,3]. A series of
studies suggested that the intracisternal infusion of Aβ
1-42 into rats was primarily deposited in the frontal cor-
tex and the hippocampus, causing memory deficits in
behavioral tasks including inhibitory avoidance task and
Morris water maze [3,4]. Thus, the intracisternal infu-
sion of Aβ 1-42 into the lateral ventricle has been used
to induce AD-like pathological and behavioral changes
in animal model [3].
Cistanche tubulosa (Schenk) R. Wight (abbreviated as
CT) is commonly used by traditional Chinese physicians
to treat forgetfulness, impotence and senile constipation
[5]. Recent studies have shown that pretreatment with
total phenylethanoid glycosides of CT could improve the
impairment of inhibitory avoidance response and neuronal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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mon carotid artery ligation in mice [6-8] via its antioxi-
dant activity and increasing the activities of intracellular
antioxidant enzymes such superoxide dismutase and
glutathione peroxidase [9]. Total phenylethanoid glyco-
sides mainly include 2’-acetylacteoside, acteoside, cistano-
sides, echinacoside and isoacteoside [10]. Echinacoside
and acteoside can prevent the memory impairment caused
by scopolamine in mice [11,12]. Therefore, we hypothe-
sized that CT may have beneficial effects in AD patients.
To test this hypothesis, we used CT extract which the
contents of phenylpropanoid glycosides were quantified to
investigate the effects against amyloid-induced histopatho-
logical and behavioral changes in an AD-like rat model.
According to a meta-analysis of Myhrer on four behav-
ioral tasks [13], acetylcholinergic and catecholaminergic
activities have a high influence on learning and memory.
The AD-like rat model causes the dysfunction of central
neurotransmitters such as acetylcholine and catechol-
amines, which is closely related to memory deficits [3,14].
Hence, we further demonstrated the role of central neuro-
transmitter function in CT extract-induced reversal of
memory impairment caused by Aβ 1-42 infusion by
measuring the levels of central neurotransmitters and
the activities of related enzymes.Methods
Preparation of plant extract
The dried materials of Cistanche tubulosa (Schenk) Wight
(Citu970429) were identified by Development Center
for Biotechnology (Taipei, Taiwan, R.O.C.) and deposited
in Sinphar Tian-Li Pharmaceutical Co., Ltd. (Hangzhou,
China). The aqueous extract of CT contains three pheny-
lethanoid glycosides, echinacoside (25.4%), acteoside
(3.8%), and isoacteoside (4.1%), which were quantified by
high performance liquid chromatography plus photodiode-
array detector according to the method of Jiang et al
[9]. CT extract was freshly prepared with sterile dis-
tilled water.Subjects
Male Sprague-Dawley rats weighing 300-350 g, obtained
from BioLASCO Taiwan Co. Ltd., were used in present
study. They were randomly housed at a density of four rats
per wire-mesh cage (39 × 26 × 21 cm) in a temperature-
(23 ± 1°C) and humidity-(60%) regulated environment with
free access to standard food in pellets and tap water and,
on a 12 h - 12 h light/dark cycle (light phase: 08:00 to
20:00 h). The experimental protocol (Protocol No. 99-
127-B) was approved by the Institutional Animal Care and
Use Committee (IACUC) of China Medical University
and the care of animal was carried out according to the
Guiding Principles for the Care and Use of LaboratoryAnimals. After 1 week of acclimatization, rats were used
for the below experiments.
AD-like rat model
The AD-like rat model was developed by infusing Aβ 1-42
into the cerebral ventricle [4]. Briefly, rats were anesthe-
tized with phenobarbital (45 mg/kg, i.p.) and positioned in
a David Kopf stereotaxic instrument. An infusion cannula
was implanted into the left cerebral ventricle (AP -1.5,
ML +0.9, V -3.6 from bregma), and a continual infusion
of Aβ 1-42 (300 pmol/day) was maintained for at least
two weeks by attaching an infusion cannula to a mini-
osmotic pump (Alzet 2002; Alza, Palo Alto, CA, USA).
Experimental schedule
After the implantation of the cannula and the attachment
of the mini-osmotic pump, Aβ 1-42 infusion began, and
this day was designated as day 0. On the next day (day 1),
the rats were orally given with sterile distilled water, CT
extract (100, 200 mg/kg) or donepezil (0.75 mg/kg)
throughout Aβ 1-42 infusion period. CT extract (100,
200 mg/kg) or donepezil (0.75 mg/kg) was also still
given to rats 1 h before the behavioral tests, including
open field test and hole test (day 7 after Aβ 1-42 infu-
sion), inhibitory avoidance test (day 8-9 after Aβ 1-42
infusion) and Morris water maze (day 10-14 after Aβ
1-42 infusion). On day 15 after Aβ 1-42 infusion, the
rats were killed 1 h after the last administration of CT
extract (100, 200 mg/kg) or donepezil (0.75 mg/kg) for
the measurement of acetylcholinesterase (AChE) and
monoamine oxidase (MAO) activities in the brain and
the levels of central neurotransmitters and their metabo-
lites. The schedule for surgery, drug treatment, and behav-
ioral tests is shown in Figure 1.
Locomotor and exploratory activities
Locomotor and exploratory activities were measured by
an open-field task (Coulbourn Instruments L.L.C., PA,
USA). Each animal was placed individually at the appar-
atus and observed for 10 min to record the movement
time, length and velocity (locomotor activity), entries
into the hole and time spent (exploratory activity) by
TruScan software v 2.07 (Coulbourn Instruments L.L.C.,
PA, USA) [15].
Inhibitory avoidance test
The inhibitory avoidance apparatus for rats (Coulbourn
Instruments L.L.C., PA, USA) was used. The room was
dark during the experimental sessions that were con-
ducted between 09:00 and 12:00. During the training trial
(day 8), each rat was placed in the light compartment with
its back to the guillotine door and the time (step-through
latency) was measured until the rat entered the dark com-
partment. After the rat entered the dark compartment,
Figure 1 Experimental schedule. LA: Locomotor activity assay, IA: Inhibitory avoidance test, MWM: Morris water maze test.
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for 2 s) was delivered through the grid floor. The rat was
removed from the dark compartment 5 s after the shock.
Then, the rat was put back into its home cage until the re-
tention trial. Twenty-four hours later, the retention trial
(day 9) was conducted. The rat was again placed in the
light compartment, the door was opened and the step-
through latency was recorded as a measure of memory re-
tention [15]. An upper cut-off time of 300 sec was set.
Morris water maze task
For the assessment of spatial performance function, the
rats were tested in a Morris water maze, which consisted
of a black circular stainless pool (a diameter of 165 cm
and a height of 60 cm), filled with 23 ± 1°C water to a
depth of 35 cm. The maze was divided geographically
into four equal quadrants and included release points in
each quadrant. The position of white rat in the black
pool was recorded by a video camera and an automated
video tracking system device equipped with EthoVision
XT software (Noldus Information Technology, Leesburg,
VA, USA). The swim path and escape latency to find the
platform were recorded for each trial. Each rat was given
two trials per day for four consecutive days (day 10 - 13
after Aβ 1-42 infusion) to find the Plexiglass hidden
platform (a diameter of 10 cm) that was situated in the
center of the northeast quadrant and submerged 1.0 cm
below the surface of the water. A trial was initiated by
placing the rat in the water facing the pool wall in one
of the four quadrants. For each trial, the rat was allowed
to swim for maximum of 120 sec to find the platform.
When successful, the rat was allowed a 30-sec rest period
on the platform. If unsuccessful within the aborted time
period, the rat was given a score of 120 sec and then phys-
ically placed on the platform and allowed the 30-sec rest
period. In either case, the rat was immediately given the
next trial after the rest period [15]. The day following four
daily sessions (day 14), the probe test was performed as a
measure of reference memory. The Plexiglass platformwas removed from the pool, and each rat was released
from the quadrant opposite to where the platform had
been located. The parameters measured from probe test
during 60 s were time and distance in each quadrant espe-
cial spent searching for the platform in the training quad-
rant, and swimming speed [15].
Aβ 1-42 immunohistochemical stain
Rats were anesthetized with sodium pentobarbital (45 mg/kg)
and perfused with saline through their left cardiac ven-
tricle, followed by 4% paraformaldehyde in physiological
saline. After postfixation, the whole brain was removed
and prepared for paraffin slices. Three brain sections
(10 μm) of each rat were obtained on a microtome (Leica
2030 Biocut). The tissues were incubated overnight at 4°C
with a mouse anti-human amyloid β protein 17-24 mono-
clonal antibody (1:300 dilution, Dakopatts A/C; Glostrup,
Denmark). Immunolabeled sections were developed with
0.05% diaminobenzidine using a Vectastain kit (Vector
Laboratories, Burlingame, CA, USA). Brain sections were
measured under 40 x magnification, and at least 20 fields
from each brain section were counted by an image
analyzer (Leica, Q500MC, Nussloch, Germany).
Measurement of cortical and hippocampal
neurotransmitter levels
For the measurement of acetylcholine levels, rats were
sacrificed by microwave irradiation. For the measure-
ment of catecholamine levels, rats were decapitated.
Their brains were rapidly removed from the skull and
immediately separated into the cortex and hippocampus
on ice according to the protocol of Glowinski and
Iversen [16]. Then, all brain tissues were homogenized
with ice-cold 0.2 M perchloric acid and centrifuged at
14,000 rpm for 15 min at 4°C. The supernatants were
collected, put into 0.22 μM Ultrafree MC centrifugal fil-
ter units (Millipore, USA) and again centrifuged for
5 min at 4°C. The collected samples were stored at -80°C
for the measurement of the concentrations of central
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ance liquid chromatography with electrochemical detec-
tion (EICOM HTEC-500, Japan).
Determination of cortical and hippocampal AChE and
MAO activity
Each cortex and hippocampus were homogenized in 9
vol ice-cold phosphate buffered saline. Homogenates
were centrifuged at 12,000 rpm for 15 min at 4°C, and
the supernatants were stored at –80°C until use. AChE
activity was measured using Ellman method [17]. Brain
homogenates were incubated with 5,5’-dithiobis(2-nitro-
benzoic acid) at 25°C for 10 min and then acetylthiocho-
line was added for color development. The production
of 5-thio-2-nitrobenzoic acid was measured at 412 nm.
AChE activity was expressed as U AChE per mg protein.
MAO-A and MAO-B activities were determined by
incubating the reaction mixture including rat brain
homogenates, 5 U/mL horseradish peroxidase, 100 μM
amplex red, and the substrate (5 mM serotonin for
MAO-A or 5 mM benzylamine for MAO-B) at 25°C for
60 min. The enzyme activity was expressed as the per-
centage of the activity relative to vehicle-infused rats
[18]. The protein content was determined with a Bio-
Rad protein assay kit using bovine serum albumin as a
standard.
Statistical analysis
The data of inhibitory avoidance test was analyzed using
a Kruskal-Wallis non-parametric one-way analysis of
variance, followed by Mann-Whitney’s U-test. The data
from spatial performance, probe test, the ratio of amyl-
oid deposition, the activities of AChE and MAO, and the
levels of central neurotransmitters and their metabolites
were subjected to a one-way analysis of variance (ANOVA)
followed by Scheff ’s test. The criterion for statistical sig-
nificance was P < 0.05 in all statistical evaluations.
Results
Effects of CT or donepezil on locomotor and exploratory
activities
There was no difference in movement time, length or
velocity between vehicle-infused and Aβ 1-42-infused
groups (P > 0.05). CT extract (100, 200 mg/kg) or done-
pezil (0.75 mg/kg) did not alter the movement time,
length or velocity of Aβ 1-42-infused rats (P > 0.05)
(Figure 2 (A) - (C)). There was slight decrease but not
statistically significant in the time spent in the hole and en-
tries into the hole between vehicle-infused and Aβ 1-42-
infused group (P > 0.05). CT extract (100, 200 mg/kg) did
not alter the time spent in the hole or entries into the hole
of Aβ 1-42-infused rats (P > 0.05). However, donepezil
at 0.75 mg/kg increased the time spent in the hole andthe entry count into the hole of Aβ 1-42-infused rats
(P < 0.05) (Figure 2 (D) and (E)).
Effects of CT or donepezil on inhibitory avoidance task
and morris water maze
In the acquisition trial of the inhibitory avoidance test,
there was no difference in the step-through latency be-
tween any of the treatment groups (data not shown).
However, a significant reduction in the step-through latency
in the retention trial was observed in Aβ 1-42-infused
groups compared to vehicle-infused group (P < 0.001).
CT extract (100, 200 mg kg) or donepezil (0.75 mg/kg)
increased the step-through latency of the retention trial
in Aβ 1-42-infused rats (P < 0.001) (Figure 3 (A)).
The spatial performance over eight trials of four training
days (from day 10 to day13 after Aβ 1-42 infusion), par-
ticularly trials 3 ~ 7, in Aβ 1-42-infused group was signifi-
cantly impaired compared to that of vehicle-infused group
(P < 0.01). CT extract (200 mg/kg) or donepezil (0.75 mg/kg)
after Aβ 1-42 infusion ameliorated the impairment of
spatial performance caused by Aβ 1-42 infusion (P < 0.05,
P < 0.01) (Figure 3 (B)).
Compared to vehicle-infused group, Aβ 1-42-infused
group showed a significant decrease in the time spent in
the platform-quadrant during training (P < 0.001). All
doses of CT extract and donepezil (0.75 mg/kg) signifi-
cantly increased the time spent in the platform-quadrant
relative to Aβ 1-42-infused group (P < 0.001) (Figure 3
(C)). In the swimming velocity, there were no differences
between vehicle-infused group, Aβ 1-42-infused group,
or CT extract or donepezil treatment groups (P > 0.05)
(Figure 3 (D)).
Effects of CT or donepezil on Aβ 1-42 deposition
The deposition of amyloid β protein in the brains of Aβ
1-42-infused rats was more than that of vehicle-infused
rats (Figure 4 (A) and (B)). CT extract (100, 200 mg/kg)
or donepezil (0.75 mg/kg) decreased the deposition of
amyloid β protein in the brains of Aβ 1-42-infused rats
(Figure 4 (C) - (E)). The effects of CT extract or donepezil
on the ratio of Aβ 1-42 deposition in the brains of Aβ
1-42-infused rats are shown in Figure 4 (F). Compared
to vehicle-infused group, Aβ 1-42-infused group showed a
significantly greater ratio of Aβ 1-42 deposition in the
brain (P < 0.01). CT extract (100, 200 mg/kg) or donepezil
(0.75 mg/kg) decreased the ratio of Aβ 1-42 deposition in
the brain of Aβ 1-42-infused rats (P < 0.05, P < 0.01).
Effects of CT or donepezil on brain neurotransmitters and
their metabolites
Aβ 1-42 continual infusion decreased cortical and hippo-
campal acetylcholine levels (P < 0.05 for cortex, P < 0.001
for hippocampus), but only decreased hippocampal cho-
line levels (P < 0.01). CT extract (200 mg/kg) or donepezil
Figure 2 Effects of CT extract (100, 200 mg/kg) or donepezil (0.75 mg/kg) on the locomotor activity including movement time (A),
movement length (B) and mean velocity (C), and the exploratory behavior including entries into holes (D) and time spent in holes (E)
in Aβ 1-42-infused rats. Columns indicate means ± SEM (N = 20). *P < 0.05 compared with Aβ 1-42-infused rats.
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pocampal acetylcholine levels in Aβ 1-42-infused rats
(P < 0.05) (Table 1).
Continuous infusion of Aβ 1-42 decreased cortical and
hippocampal DA levels (P < 0.01), but only decreased
hippocampal NE levels (P < 0.05). CT extract (100 and200 mg/kg) only reversed the decrease in DA levels in
the hippocampus of Aβ 1-42-infused rats (P < 0.05).
Donepezil did not alter the decrease in hippocampal
DA levels (P > 0.05), but exaggerated the decrease in
hippocampal NE levels in Aβ 1-42-infused rats (P < 0.01)
(Table 1).
Figure 3 Effects of CT extract (100, 200 mg/kg) or donepezil (0.75 mg/kg) on the step-through latency of the inhibitory avoidance task
(A), the spatial performance (B), probe test (C), and swimming velocity (D) of the Morris water maze in Aβ 1-42-infused rats. Columns
indicate means ± SEM (N = 20). *P < 0.05, **P < 0.01, ***P < 0.001 compared with Aβ 1-42-infused rats.
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MAO-B activity
Continuous infusion of Aβ 1-42 increased cortical and
hippocampal AChE activities (P < 0.05 for hippocampus,
P < 0.01 for cortex). CT extract (200 mg/kg) or donepezil
(0.75 mg/kg) only reversed the increase in cortical AChE
activity in Aβ 1-42-infused rats (P < 0.05 for donepezil,
P < 0.01 for CT) (Figure 5 (A) and (B)).
Continuous infusion of Aβ 1-42 increased cortical MAO-A
and MAO-B activity (Figure 5 (C) and (E), P < 0.05, P < 0.01),
but decreased hippocampal MAO-A and MAO-B activities
in the rats (Figure 5 (D) and (F), P < 0.05). CT extract at
200 mg/kg only reversed the increase in the cortical
MAO-A activity in Aβ 1-42-infused rats (Figure 5 (C),P < 0.01). Donepezil (0.75 mg/kg) did not change the
alteration of MAO-A and MAO-B activities in Aβ 1-
42-infused rats (Figure 5 (C) - (F), P > 0.05).
Discussion
Many reports from cell culture assays and animal experi-
ments evidenced that Aβ is the key protein in AD patients
[2,3]. Aβ 1-42 induced neuronal damage and apoptosis via
oxidative stress in vitro [2,3]. Intracisternal injection of Aβ
1-42 into rats produced memory impairment, changes in
brain morphology, and cholinergic neuronal degeneration
[3,4]. In this study, the continual infusion of Aβ 1-42 to
the cerebral ventricle by an osmotic pump (Alzet 2002)
caused behavioral deficits including exploratory behavior,
Figure 4 Effects of CT extract (100, 200 mg/kg) or donepezil (0.75 mg/kg) on the Aβ 1-42 deposition in Aβ 1-42-infused rats. (A) Vehicle-infused
group, (B) Aβ 1-42-infused group, (C) CT extract (100 mg/kg)-treated group, (D) CT extract (200 mg/kg)-treated group, (E) donepezil (0.75 mg/kg)-treated
group, (F) the ratio of amyloid depsotion. Columns indicate means ± SEM (N = 6). *P< 0.05, **P< 0.01 compared with Aβ 1-42-infused rats.
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Morris water maze in rats. These symptoms were similar
to previous reports [3,4]. Donepezil, a selective AChE
inhibitor, possess neuroprotective activity against Aβ-
induced toxicity in vitro and in vivo [19,20]. Our present
data are consistent with the above report [20] showing
that donepezil ameliorated the behavior deficits caused by
Aβ 1-42 infusion in rats. The intra-gastric administration
of CT extract (100, 200 mg/kg) throughout Aβ 1-42 infu-
sion period ameliorated the observed behavior deficits
caused by Aβ 1-42. This memory-improving effect is con-
sistent with other reports showing that total phenyletha-
noid glycosides of Cistanche species could protect the
impairment of inhibitory avoidance response caused by an
acute intracisternal injection of Aβ 25-35 in mice [6].
Recent clinical report also indicated that AD patients
given with CT glycosides for 48 weeks showed no ex-
acerbation of cognitive function [21]. Moreover, CT extract
at used dosage (100, 200 mg/kg) contained echinacoside
(25.4, 50.8 mg), acteoside (3.8, 7.6 mg) and isoacteoside (4.1,8.2 mg) according to quantity assay performed in this
study. Echinacoside (50 mg/kg) and acteoside (1 mg/kg)
can prevent the memory impairments caused by sco-
polamine in mice [11,12]. Thus, we suggest that CT is
a potential anti-amnesic and anti-dementia plant when
it is quantified and standardized through its phenyletha-
noid glycosides, particularly echinacoside, acteoside and
isoacteoside.
According to amyloid cascade hypothesis, memory defi-
cits caused by Aβ are due to intracellular oxidative stress
and neuronal apoptosis promoted by Aβ formation and
subsequent aggregation and deposition [2,3]. Aβ depos-
ition is closely associated with the dysfunction of central
cholinergic neuronal circuits in the basal forebrain [2,3].
The dysfunction of central cholinergic neuronal systems,
including decreased brain acetylcholine levels and an up-
regulation of AChE activity, has been shown to be related
to the degrees of amnesia and Aβ deposition in AD brain
[2,3]. According to our above results, we further inves-
tigated the effects of CT extract or donepezil on Aβ-
Table 1 Effects of CT extract (100, 200 mg/kg) or donepezil (0.75 mg/kg) on the levels of cortical and hippocampal
neurotransmitters and their metabolites in Aβ 1-42-infused rats
The levels in cortex (nmol/mg protein for ACh and choline, ng/g protein for other transmitters)
ACh Choline MHPG NE DOPAC HVA DA
Vehicle 224.25 ± 25.55** 629.00 ± 98.35 26.35 ± 2.72 15.68 ± 0.76 16.75 ± 1.70* 3.71 ± 0.58 3.92 ± 0.44**
Aβ 1-42 141.35 ± 7.95 553.10 ± 31.55 23.27 ± 1.97 13.86 ± 1.29 11.66 ± 1.13 2.76 ± 0.43 2.33 ± 0.28
CT extract
100 mg/kg 145.98 ± 18.78 716.40 ± 69.81 29.91 ± 4.91 15.94 ± 1.30 13.89 ± 3.03 4.29 ± 0.93 2.95 ± 0.65
200 mg/kg 181.49 ± 13.71* 693.45 ± 48.05 24.51 ± 4.16 10.31 ± 1.07 9.50 ± 2.10 2.98 ± 0.85 2.23 ± 0.33
Donepezil 168.32 ± 6.58* 467.26 ± 32.85 15.16 ± 2.51* 10.73 ± 2.33 10.49 ± 2.38 2.42 ± 0.78 3.10 ± 0.46
The levels in hippocampus (nmol/mg protein for ACh and choline, ng/g protein for other transmitters)
ACh Choline MHPG NE DOPAC HVA DA
Vehicle 72.88 ± 8.64*** 295.26 ± 18.06** 639.83 ± 53.38 63.64 ± 2.56* 5.87 ± 0.92 3.68 ± 0.41 5.36 ± 0.75***
Aβ 1-42 28.45 ± 2.62 173.10 ± 18.15 639.23 ± 68.26 52.67 ± 4.21 5.13 ± 0.80 3.39 ± 0.36 1.00 ± 0.21
CT extract
100 mg/kg 43.48 ± 3.14 238.20 ± 23.91 785.42 ± 139.84 57.98 ± 10.69 4.98 ± 0.78 3.90 ± 0.61 2.40 ± 0.65*
200 mg/kg 50.44 ± 8.98* 234.69 ± 13.26 704.84 ± 59.68 63.21 ± 4.79 5.98 ± 1.90 3.78 ± 0.64 3.09 ± 1.27*
Donepezil 51.11 ± 9.54* 177.69 ± 46.80 455.27 ± 46.81* 32.80 ± 3.88*** 3.19 ± 1.00 2.45 ± 0.33 1.33 ± 0.37
Columns indicate means ± SEM (N = 6). *P < 0.05, **P < 0.01, ***P < 0.001 compared with Aβ 1-42-infused rats.
Wu et al. BMC Complementary and Alternative Medicine 2014, 14:202 Page 8 of 11
http://www.biomedcentral.com/1472-6882/14/202induced pathological changes in rats. We found that
Aβ 1-42 continual infusion caused a major pathological
change in Aβ deposition around hippocampus and pre-
frontal cortex and in a significant associated biochem-
ical alteration: a decrease in acetylcholine and choline
levels and an up-regulation of AChE activity particu-
larly in hippocampal areas. These pathological symp-
toms were similar to other reports [4,22] showing that
intracisternal injection of Aβ 1-42 over 2 weeks causes
Aβ deposition in rat brain using immunohistochemical
stain, and then causes an up-regulation in AChE activity
within and around senile plaques. This up-regulation en-
courages the assembly of Aβ into fibrils, and these Aβ fi-
brils ultimately lead to Aβ neurotoxicity and particularly
cholinergic dysfunction [23]. In Aβ 1-42-infused rats,
donepezil decreased the ratio of Aβ deposition and the al-
teration in cortical AChE activity, and restored ACh levels
in all brain areas. Our present data were consistent with
another report [19,20] showing that donepezil might in-
hibit AChE activation to produce neuroprotective and
memory-improving effects against Aβ 1-42. CT extract
(100, 200 mg/kg) also decreased the deposition of Aβ, es-
pecially in hippocampal areas, but only 200 mg/kg dosage
reversed the alterations in cortical AChE activity and the
decrease in cortical and hippocampal acetylcholine levels.
From these pathological and biochemical results, we sug-
gested that CT extract at 200 mg/kg reversed cortical and
hippocampal cholinergic function by decreasing the de-
position of Aβ. Other reports indicated that total pheny-
lethanoid glycosides of Cistanche species or acteoside
could protect the memory deficits or neuronal damage
caused by Aβ 25-35 through an antioxidant mechanismand decreasing the ratio of Bax/Bcl2 in vivo or in vitro
[6,24]. Recent report further indicated that acteoside
inhibited Aβ 1-42 aggregation in a dose-dependent man-
ner by using the thioflavin-T assay [25]. Echinacoside de-
creased AChE activity in SAMP/8 mice [12]. Thus, we
suggest that the memory-improving effects of CT extract
might be related to decrease Aβ deposition and neurotox-
icity, which leads to a reversal of negative changes in cor-
tical and hippocampal cholinergic function.
Clinical researchers found that AD patients have com-
plex neurochemical disturbances including the catechol-
aminergic, cholinergic and glutaminergic neuronal systems
[26]. Some reports also found that AD patients have in-
creased MAO-B activity compared to healthy controls,
and this increased MAO-B activity might reflect abnor-
malities in the dopaminergic systems [27]. In AD-like rat
model, Aβ 1-42 also causes catecholaminergic dysfunction
[14]. Some nootropics or selegiline improved Aβ-induced
memory deficits via enhancing catecholaminergic activity
or modulating MAO activities [4,28]. In this study, Aβ
1-42 continual infusion also caused a decrease in cortical
and hippocampal DA levels and in hippocampal NE levels.
We also found that Aβ 1-42 continual infusion led to a dif-
ferential alteration of cortical and hippocampal MAO
activities, which included an up-regulation in cortical
MAO-A and MAO-B activities and a downregulation in
hippocampal MAO-A and MAO-B activities. These
pathological symptoms of catecholaminergic dysfunction
were similar to other reports [14,27]. Donepezil did not
alter these catecholaminergic change caused by Aβ 1-42
infusion, but decreased hippocampal NE and MHPG
levels compared to Aβ 1-42-infused rats This data is
Figure 5 Effects of CT extract (100, 200 mg/kg) or donepezil (0.75 mg/kg) on the AChE (A and B), MAO-A (C and D) and MAO-B (E and
F) activity in the cortex (A, C and E) and hippocampus (B, D and F) of Aβ 1-42-infused rats. Columns indicate means ± SEM (N = 6).
*P < 0.05, **P < 0.01 compared with Aβ 1-42-infused rats.
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pezil possesses memory-improving effects against Aβ 1-42
that act mainly through its selective AChE inhibiting effects
but it possibly causes region-specific changes in some neu-
rotransmitters. CT extract only reversed the decrease in
hippocampal DA levels and the up-regulation of cortical
MAO-A activity caused by Aβ 1-42 infusion. Hence, we
suggest that CT extract at 200 mg/kg reversed the negative
effects on hippocampal dopaminergic function mainly by
decreasing the deposition of Aβ in the hippocampal areas.
However, donepezil also decreased the deposition of Aβ,
but did not affect the hippocampal dopaminergic function.
Conclusion
CT is a potential anti-amnesic and anti-dementia plant
based on our present data and other reports [6-8,21].
The contents of echinacoside and acteoside in this used
dosage of CT extract is sufficient to produce memory-
improving effects in SAMP/8 mice or scopolamine-
induced amnesia [11,12]. Hence, we further suggest that,
as an anti-dementia plant, it is important to standardize
the content range of echinacoside, acteoside and isoacteo-
side in CT extract. Furthermore, the memory-improving
mechanism of CT extract, which is different from that of
donepezil that it decreased Aβ deposition and cholinergic
dysfunction by inhibiting AChE activation and activating
nicotinic receptors and phosphoinositide 3-kinase/Akt
pathways [19,20], is due to the decrease in Aβ deposition
and reversal of the cholinergic and hippocampal dopamin-
ergic dysfunction. Moreover, other reports have indicated
that total phenylethanoid glycosides of the Cistanche spe-
cies possess neuroprotective and memory-enhancing ef-
fects through their antioxidant and neurotrophic activities
[9,29,30]. Echinacoside and acteoside also possess neuro-
protective effects in H2O2- MPTP- or Aβ 25-35-induced
neurotoxicity via antioxidant and neurotrophic activities
[24,31,32]. Hence, whether the protective effect of CT ex-
tract in AD-like rat model acts through anti-aggregating,
neuroprotective or neurotrophic effects against Aβ should
be investigated in the future.
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